A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
We are excited to announce that we are conducting a clinical trial with Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., for the treatment of head and neck squamous cell carcinoma. This clinical study compares Lenvima (Lenvatinib) in combination with Keytruda (pembrolizumab) against standard chemotherapy and Lenvatinib monotherapy for people who have progressed after platinum therapy and immunotherapy.
It is the purpose of this study to test the combination of these drugs to see if the combination works better against cancer than standard chemotherapy.
Lenvatinib blocks the growth of new blood vessels that are used to support the growth of cancer cells. By stopping the formation of these new blood vessels cancer cells cannot get the nutrients they need to grow.
Pembrolizumab is a type of immunotherapy that stimulates the body’s immune system to fight cancer.
Lenvatinib has FDA approval for use in liver, thyroid and kidney cancers. Pembrolizumab has FDA approval for use in many types of cancer including head and neck cancer.
If you are interested in more information on this study, please contact us. Refer to the Merck Study Protocol MK-7902-009. You can also find information on this study by going to clinicaltrials.gov website and searching for NCT04428151.